GRAIL

GRAIL, Inc. is a biotechnology and healthcare company based in Menlo Park, California, focused on early cancer detection. The company aims to identify cancer at a stage when it can be cured, using innovative technologies to detect multiple cancer types in their early stages. GRAIL employs next-generation sequencing, large-scale clinical studies, and advanced machine learning to enhance the understanding of cancer biology. The flagship product, the Galleri test, is a liquid biopsy designed to detect signals from over 50 types of cancer through targeted methylation patterns in circulating tumor DNA. GRAIL also develops solutions for accelerating cancer diagnoses and monitoring treatment through blood-based assays. The company collaborates with leading healthcare institutions and offers clinical support services to integrate its testing into patient care. GRAIL is committed to innovation and scientific rigor in the fight against cancer.